(Q38261568)

1 September 2017

1 reference

title

The PD-1 pathway as a therapeutic target to overcome immune escape mechanisms in cancer (English)

1 reference

evasion of host immune response

1 September 2017

1 reference

2

Roy S Herbst

1 reference

1 September 2017

Brian S Henick

1

1 reference

PubMed ID

25331677

1 September 2017

Sarah B Goldberg

series ordinal

3

1 reference

PubMed ID

25331677

1 September 2017

language of work or name

English

0 references

publication date

21 October 2014

1 reference

Expert Opinion on Therapeutic Targets

1 September 2017

1 reference

1 September 2017

18

1 reference

1 September 2017

12

1 reference

1 September 2017

1407-1420

1 reference

Immunosuppressive networks in the tumour environment and their therapeutic relevance

1 September 2017

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.955794

Co-inhibitory molecules of the B7-CD28 family in the control of T-cell immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.955794

Expression of the PD-1 antigen on the surface of stimulated mouse T and B lymphocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.955794

Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.955794

B7-H1, a third member of the B7 family, co-stimulates T-cell proliferation and interleukin-10 secretion

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.955794

PD-L2 is a second ligand for PD-1 and inhibits T cell activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.955794

21 January 2018

The B7 family revisited

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.955794

The B7 family of ligands and its receptors: new pathways for costimulation and inhibition of immune responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.955794

Negative regulators of T-cell activation: potential targets for therapeutic intervention in cancer, autoimmune disease, and persistent infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.955794

PD-1 and its ligands in tolerance and immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.955794

B7-H1 determines accumulation and deletion of intrahepatic CD8(+) T lymphocytes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.955794

Development of lupus-like autoimmune diseases by disruption of the PD-1 gene encoding an ITIM motif-carrying immunoreceptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.955794

Autoimmune dilated cardiomyopathy in PD-1 receptor-deficient mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.955794

Autoantibodies against cardiac troponin I are responsible for dilated cardiomyopathy in PD-1-deficient mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.955794

Inhibitory B7-family molecules in the tumour microenvironment

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.955794

PD-1 and PD-1 ligands: from discovery to clinical application

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.955794

PD-1 signaling in primary T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.955794

B7-H1 is a ubiquitous antiapoptotic receptor on cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.955794

Blockade of B7-H1 improves myeloid dendritic cell–mediated antitumor immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.955794

Cell surface signaling molecules in the control of immune responses: a tide model.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.955794

Programmed death-1 ligand 1 interacts specifically with the B7-1 costimulatory molecule to inhibit T cell responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.955794

B7-H1/CD80 interaction is required for the induction and maintenance of peripheral T-cell tolerance

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.955794

Programmed death-1 (PD-1):PD-ligand 1 interactions inhibit TCR-mediated positive selection of thymocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.955794

Absence of Programmed Death Receptor 1 Alters Thymic Development and Enhances Generation of CD4/CD8 Double-Negative TCR-Transgenic T Cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.955794

Facilitation of beta selection and modification of positive selection in the thymus of PD-1-deficient mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.955794

SHP-1 and SHP-2 associate with immunoreceptor tyrosine-based switch motif of programmed death 1 upon primary human T cell stimulation, but only receptor ligation prevents T cell activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.955794

PD-1 is a regulator of virus-specific CD8+ T cell survival in HIV infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.955794

Severe functional impairment and elevated PD-1 expression in CD1d-restricted NKT cells retained during chronic HIV-1 infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.955794

Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.955794

B7 family molecules: novel immunomodulators at the maternal-fetal interface

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.955794

Intrinsic and extrinsic control of peripheral T-cell tolerance by costimulatory molecules of the CD28/ B7 family

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.955794

Control of peripheral T-cell tolerance and autoimmunity via the CTLA-4 and PD-1 pathways.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.955794

Tumor B7-H1 is associated with poor prognosis in renal cell carcinoma patients with long-term follow-up.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.955794

Blockade of programmed death-1 ligands on dendritic cells enhances T cell activation and cytokine production

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.955794

B7-H1 is expressed by human endothelial cells and suppresses T cell cytokine synthesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.955794

B7-H1 expression on non-small cell lung cancer cells and its relationship with tumor-infiltrating lymphocytes and their PD-1 expression

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.955794

Programmed death ligand-1 expression in non-small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.955794

PD-1 is expressed by tumor-infiltrating immune cells and is associated with poor outcome for patients with renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.955794

Programmed cell death 1 ligand 1 and tumor-infiltrating CD8+ T lymphocytes are prognostic factors of human ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.955794

Tumor antigen-specific CD8 T cells infiltrating the tumor express high levels of PD-1 and are functionally impaired

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.955794

Overall survival and PD-L1 expression in metastasized malignant melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.955794

Clinical impact of programmed cell death ligand 1 expression in colorectal cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.955794

Colocalization of inflammatory response with B7-h1 expression in human melanocytic lesions supports an adaptive resistance mechanism of immune escape

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.955794

PD-L1 expression in the Merkel cell carcinoma microenvironment: association with inflammation, Merkel cell polyomavirus and overall survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.955794

Peripheral CD45RO, PD-1, and TLR4 expression in metastatic colorectal cancer patients treated with bevacizumab, fluorouracil, and irinotecan (FOLFIRI-B).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.955794

PD-1/PD-L blockade prevents anergy induction and enhances the anti-tumor activities of glycolipid-activated invariant NKT cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.955794

Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.955794

The new B7s: playing a pivotal role in tumor immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.955794

Plasmacytoid dendritic cells from mouse tumor-draining lymph nodes directly activate mature Tregs via indoleamine 2,3-dioxygenase

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.955794

Monoclonal antibodies: versatile platforms for cancer immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.955794

Anti-programmed death-1 synergizes with granulocyte macrophage colony-stimulating factor--secreting tumor cell immunotherapy providing therapeutic benefit to mice with established tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.955794

CTLA-4 and PD-1 receptors inhibit T-cell activation by distinct mechanisms

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.955794

The immunogenicity of humanized and fully human antibodies: residual immunogenicity resides in the CDR regions

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.955794

Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.955794

Phase I safety and pharmacokinetic study of CT-011, a humanized antibody interacting with PD-1, in patients with advanced hematologic malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.955794

Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.955794

Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.955794

Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.955794

Meta-analysis of phase II cooperative group trials in metastatic stage IV melanoma to determine progression-free and overall survival benchmarks for future phase II trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.955794

Results of a phase III, randomized, placebo-controlled study of sorafenib in combination with carboplatin and paclitaxel as second-line treatment in patients with unresectable stage III or stage IV melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.955794

Ipilimumab plus dacarbazine for previously untreated metastatic melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.955794

Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.955794

Safety, activity, and immune correlates of anti-PD-1 antibody in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.955794

Safety and Tumor Responses with Lambrolizumab (Anti–PD-1) in Melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.955794

Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.955794

Postoperative adjuvant chemotherapy use in patients with stage II/III rectal cancer treated with neoadjuvant therapy: a national comprehensive cancer network analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.955794

Randomized phase II trial of Onartuzumab in combination with erlotinib in patients with advanced non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.955794

Nivolumab plus ipilimumab in advanced melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.955794

Anti-tumoral efficacy of therapeutic human anti-KIR antibody (Lirilumab/BMS-986015/IPH2102) in a preclinical xenograft tumor model

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.955794

Immune inhibitory molecules LAG-3 and PD-1 synergistically regulate T-cell function to promote tumoral immune escape

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.955794

Dendritic/tumor fusion cells as cancer vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.955794

PD-1 blockade by CT-011, anti-PD-1 antibody, enhances ex vivo T-cell responses to autologous dendritic cell/myeloma fusion vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.955794

Dendritic cell-tumor fusion vaccines for renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.955794

Genome-wide analysis of transcriptional regulators in human HSPCs reveals a densely interconnected network of coding and noncoding genes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.955794

Mast cell sarcoma: a rare and aggressive entity--report of two cases and review of the literature

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.955794

From node to pathway blockade: lessons learned from targeting mammalian target of rapamycin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.955794

Safety, efficacy, and biomarkers of nivolumab with vaccine in ipilimumab-refractory or -naive melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.955794

Combination epigenetic therapy has efficacy in patients with refractory advanced non-small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.955794

Cancer immunotherapy comes of age

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.955794

Cancer immunotherapy comes of age

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.955794

Induced expression of PD-1, a novel member of the immunoglobulin gene superfamily, upon programmed cell death

21 January 2018

1 reference

24 May 2022

https://opencitations.net/index/coci/api/v1/citations/10.1002/J.1460-2075.1992.TB05481.X

Identifiers

DOI

10.1517/14728222.2014.955794

1 reference

1 September 2017

1 reference

PubMed ID

25331677